

UK PHILANTHROPISTS SIMONE AND PAUL COMMINS DONATED GBP 100,000 FOR DELTAREX-G CANCER RESEARCH

Working towards a cure for advanced sarcoma

LOS ANGELES, CA, USA, July 17, 2023

/EINPresswire.com/ --

Who: Simone and Paul Commins, a UK businessman who has curated a successful trading career, donated GBP 100,000 to Aveni Foundation for [DeltaRex-G](#) cancer research. This was inspired by their niece, Hope Stringer, with advanced sarcoma who wishes to receive DeltaRex-G, a tumor-targeted gene therapy that has gained Expanded Access Authorization from the USFDA for the treatment of patients with advanced sarcoma and pancreatic cancer.

DeltaRex-G has induced long term survival (>10 years) in patients with chemotherapy failed Stage 4 soft tissue sarcoma, osteosarcoma, pancreatic cancer, breast cancer and B cell lymphoma (Chawla et al., Anticancer Res. 43: 2383-2391 (2023).

doi:10.21873/anticancer.16406).

DeltaRex-G was created over a decade ago by local scientists Drs. Erlinda M. Gordon and Frederick L. Hall. It is ONLY available at the Sarcoma Oncology Center in Santa Monica CA. DeltaRex-G is supplied by the Aveni Foundation, a 501(c)(3) public charity founded by Dr. Gordon in 2018, that raises money through generous benefactors to make the medicine. It is not available through drug or insurance companies.

Note Best: This press release is in compliance with HIPAA.

To donate: Click on the DONATE button at www.avenifoundation.org

For further information, please visit our websites: www.avenifoundation.org, contact Dr.Gordon



Hope and husband Sean on Santa Monica Beach, California

at egordon@avenifoundation.org or
egordon@sarcomaoncology.com.


“

He surfs, I meditate. Getting
me out of my own head first
thing every day.

”

Hope Stringer

Erlinda Gordon
Aveni Foundation
+1 818-726-3278
[email us here](#)





AVENI FOUNDATION

The Aveni Foundation mission is to expedite development of gene-targeted technologies for cancer and other unmet medical needs.

This press release can be viewed online at: <https://www.einpresswire.com/article/644769284>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.